HOME　/　PEPTIDES　/　PNC-27
PEPTIDE RESEARCH TOPIC

PNC-27 Research Peptide

PNC-27 is an experimental peptide studied in cancer-cell membrane biology. Explore HDM2 interactions, laboratory findings, related peptides, and translational limitations.

TOPIC OVERVIEW

About PNC-27

Identity and names

PNC-27 is a designed peptide containing a p53-derived region and a membrane-active leader. PNC-28 is a related but distinct peptide.

Compound type

It is an experimental chimeric peptide. Its identity depends on the full sequence and characterization, not merely the p53-derived component.

Mechanism

Studies investigate membrane-associated HDM2 binding and membrane disruption in cancer-cell models. This is different from assuming a standard intracellular p53 treatment mechanism.

Research focus and evidence

Published experiments include cell systems and mechanistic analyses. Activity against laboratory cancer cells does not establish patient response or tumor selectivity in all settings.

Regulatory status and limits

The cited studies do not establish an approved cancer therapy or human dosing protocol. Clinical translation requires independent efficacy, exposure, and safety evidence.

Topics covered
  • p53-derived peptide design
  • membrane-associated HDM2
  • membrane disruption
  • PNC-27 versus PNC-28
  • preclinical cancer evidence
Common names and related terms: PNC-27, PNC 27
RESEARCH SUMMARY

What Is PNC-27?

LAST VERIFIEDOctober 7, 2026

A foundational study linked PNC-27 to membrane-associated HDM2 in tested cancer-cell models. The work supports a proposed laboratory mechanism, rather than demonstrating that the peptide treats cancer in patients. PNC-27 membrane HDM2 study

A subsequent leukemia-cell investigation extended this question to K562 cells and examined membrane-dependent cell death. That extension remains model-specific and should not be presented as a clinical leukemia outcome. PNC-27 leukemia-cell study

EVIDENCE PROFILE

PNC-27 Research Evidence

A concise view of registered clinical research, PubMed-indexed literature, evidence stage, and important limitations.

LAST VERIFIEDOctober 7, 2026
Registered records0
Active studies0
Completed studies0
PubMed records23
Compound typeIt is an experimental chimeric peptide. Its identity depends on the full sequence and characterization, not merely the p53-derived component.
AliasesPNC-27, PNC 27
Evidence stagePublished experiments include cell systems and mechanistic analyses. Activity against laboratory cancer cells does not establish patient response or tumor selectivity in all settings.
U.S. regulatory contextThe cited studies do not establish an approved cancer therapy or human dosing protocol. Clinical translation requires independent efficacy, exposure, and safety evidence.
CLINICAL REGISTRY

Selected registered research

No matching intervention record was found in ClinicalTrials.gov during this verification. This does not mean that no research exists.

INDEXED LITERATURE

Selected PubMed records

PMID 200806802010 Feb 2 · Proceedings of the National Academy of Sciences of the United States of America

Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.

PMID 251170932014 Summer · Annals of clinical and laboratory science

The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.

PMID 356256822022 Apr 20 · Biomedicines

PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.

How to interpret this profile

Registry and publication counts describe discoverable records, not proof of effectiveness or safety. Study design, compound identity, population, endpoints, and regulatory context must be reviewed individually.

Primary sources: ClinicalTrials.gov (defined search) · PubMed (defined query)Checked October 7, 2026. Counts include interventional registry records with an explicit matching intervention name or alias; broad search results, biomarker-only observations, and unrelated compounds are excluded. Active includes recruiting, not yet recruiting, active not recruiting, and enrolling by invitation. PubMed is the linked title/abstract query count, not a number of clinical trials or a measure of evidence quality.

Displayed records are selected for relevance and recency; the page does not reproduce the complete source databases.

START HERE

Essential PNC-27 guides

What Is PNC-27? Research, Safety, and StatusWhat is PNC-27? It is a synthetic peptide derived from p53 that targets HDM2-overexpressing cancer cells in lab studies. It is not FDA-approved for human use.PNC-27 Clinical Trials: Status, Evidence, and SafetyPNC-27 clinical trials: none are registered in humans. Learn what the research shows, how it compares to PNC-28, and why it stays a lab chemical.PNC-27 Peptide Sciences: Research Overview & SafetyPNC-27 peptide sciences research overview: what this p53-derived peptide does in lab studies, how it compares to PNC-28, and safety and legal points.
PNC-27 KNOWLEDGE ARTICLESPage 1 of 1
02
KNOWLEDGE ARTICLE

PNC-27 and Pancreatic Cancer: What Research Shows

PNC-27 and pancreatic cancer: explore how this peptide targets cancer cells, preclinical research findings, and important safety considerations for patients.

↗
05
KNOWLEDGE ARTICLE

PNC-27 and Prostate Cancer: What Research Shows

PNC-27 prostate cancer research is preclinical: no human trials and no FDA approval. Learn what lab studies show, how it compares to PNC-28, and the risks.

↗
07
KNOWLEDGE ARTICLE

Where to Buy PNC-27 Peptide: Sourcing Guide

Looking for where to buy PNC-27? Compare research peptide suppliers, typical prices, purity testing, and legal status before you order a vial.

↗
09
KNOWLEDGE ARTICLE

PNC-27 Side Effects: What Research Actually Shows

PNC-27 side effects are not documented in humans because the peptide has never been tested in clinical trials. Here's what lab data and safety research show.

↗
10
KNOWLEDGE ARTICLE

What Is PNC-27? Research, Safety, and Status

What is PNC-27? It is a synthetic peptide derived from p53 that targets HDM2-overexpressing cancer cells in lab studies. It is not FDA-approved for human use.

↗
11
KNOWLEDGE ARTICLE

PNC-27 Benefits: What Research Shows So Far

PNC-27 benefits are studied in lab research, not approved for human use. Learn what early PNC-27 peptide studies suggest about cancer cell targeting.

↗
13
KNOWLEDGE ARTICLE

PNC-27 Dosage: What Research Actually Shows

There is no established PNC-27 dosage for humans. Here's what lab studies actually report, how 5 mg vials are reconstituted, and why human data is missing.

↗
15
KNOWLEDGE ARTICLE

PNC-27 Breast Cancer Research: What Studies Show

PNC-27 breast cancer research is preclinical: lab and mouse studies only, no human trials and no FDA approval. Here is what the evidence shows so far.

↗